Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mannheimia haemolytica serotype A1 is a Gram-negative bacterial pathogen and the principal causative agent of bovine respiratory disease complex (BRDC), one of the most economically significant infections in cattle. The bacterium normally resides as a commensal organism in the upper respiratory tract of healthy ruminants but can transition to a pathogenic state under stress conditions such as transport, environmental changes, or viral co-infections. Serotype A1 possesses unique virulence determinants that distinguish it from other serotypes, including an invasion mechanism that allows it to penetrate differentiated bovine respiratory epithelial cells—a capability absent in serotype A2. The primary virulence factor is leukotoxin, a calcium-dependent toxin that triggers inflammatory responses leading to lung edema and necrosis. Understanding the molecular basis of A1's pathogenicity is critical for developing vaccines and antimicrobial strategies, particularly given increasing antimicrobial resistance in clinical isolates.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mannheimia haemolytica serotype A1 (M. haemolytica A1).